Table 1

Characteristics of included or non-included patients

Training Group

Validation Group

Significance p training vs validation included


Characteristic

Included N = 160

Non-included N = 78

Significance p

Included N = 97

Non-included N = 69

Significance p


Demographicsmean (se)or n (%)

Age at biopsy, years

52.9 (0.89)

54.2 (1.37)

0.34

48.5 (1.3)

49.1 (1.5)

0.72

0.01

Male

96 (60)

47 (60)

0.36

57 (59)

38 (69)

0.64

0.84

Height, meter

1.68 (0.01)

1.66 (0.01)

0.20

1.69 (0.01)

1.67 (0.01)

0.27

0.81

Weight, kg

83.6 (1.2)

76.3 (2.6)

0.01

77.4 (1.5)

74.0 (1.9)

0.04

0.002

Body Mass Index, kg/m2

29.6 (0.4)

27.6 (0.9)

0.03

27.1 (0.5)

26.4 (0.6)

0.11

< 0.0001

Metabolic factor (%)

Diabetes

65/160 (41)

12/78 (15)

< 0.0001

31/97 (32)

15/69 (22)

0.62

0.0002

Arterial Hypertension

53/160 (33)

6/23 (26)

15/97 (16)

16/69 (23)

0.21

0.002

Body Mass Index greater than 27 kg/m2

101/160 (63)

16/34 (47)

43/97 (44)

22/69 (32)

0.11

0.003

Triglycerides greater than 1.5

70/160 (44)

20/54 (37)

34/97 (35)

15/69 (22)

0.06

0.17

HDL cholesterol lower than 40 mg/L

36/151 (24)

6/38 (16)

15/94 (16)

15/66 (23)

0.28

0.14

Metabolic factor

None

1/160 (1)

22/78 (28)

2/97 (2)

0/69

0.23

0.30

At least one

159/160 (99)

56/78 (72)

95/97 (98)

69/69

Alcohol consumption, n (%)

No

114/160 (71)

61/78 (78)

0.25

57/97 (59)

41/69 (59)

Yes

46/160 (29)

17/78 (22)

40/97 (41)

28/69 (41)

0.63

0.04

Fibrosis stage, n (%)

Non advanced fibrosis

121/160 (76)

71/75 (95)

0.0001

66/97(68)

51/69(74)

0.48

0.12

No fibrosis

69/160 (41)

50/75 (67)

25/97 (27)

21/69 (30)

Fibrosis perisinusoidal or periportal

52/160 (33)

21/75 (28)

41/97 (41)

30/69 (43)

A: mild, zone 3, perisinusoidal

29/160 (18)

19/75 (25)

16/97 (19)

18/69 (25)

B: moderate, zone 3, perisinusoidal

1/160 (1)

2/75 (3)

15/97 (15)

0/69 (0)

C: portal/periportal

22/160 (14)

0/75 (0)

10/97 (22)

12/69 (18)

Advanced Fibrosis

39/160 (24)

4/75 (3)

31/97 (32)

18/69(26)

Perisinusoidal and portal/periportal

20/160 (13)

1/75(1)

15/97 (15)

13/69 (19)

Bridging

10/160 (6)

1/75 (1)

12/97 (12)

2/69 (3)

Cirrhosis

9/160 (6)

2/75 (3)

4/97 (4)

3/69 (4)

Non alcoholo-steato-hepatitis (Nash), n (%)

No

57/160 (36)

39/75 (52)

0.0001

41/97 (42)

NA

NA

0.04

Borderline

75/160 (47)

27/75 (36)

21/97 (22)

NA

Yes

28/160 (17)

9/75 (12)

35/97 (36)

NA

Steatosis

< 5%

10/160 (6)

24/75 (32)*

0.0001

19/97 (20)**

13/69 (19)

0.38

< 0.0001

5–32

56/160 (35)

16/75 (21)

22/97 (23)

27/69 (39)

33–65

46/160 (29)

16/75 (21)

27/97 (28)

10/69 (14)

66–100

48/160 (30)

19/75 (25)

29/97 (30)

19/60 (28)

Interval between biopsy and serum, median (95%CI), Range days

0[0; 1] -87;+89

0[-4; 1] -538; +540

< 0.0001

0[0; 0] -24;+49

0[0; 0] -42; +40

0.90

0.07

Biopsy qualitymean (se)

Sample size

20.1 (0.5)

19.3 (0.8)

0.33

17.7 (0.7)

21.4 (0.9)

0.001

0.002

Number of fragment

2.2 (0.2)

2.4 (0.2)

0.88

2.3 (0.2)

2.2 (0.2)

0.79

0.61

Number of portal tracts

16.4 (0.6)

15.5 (0.9)

0.28

13.6 (0.6)

17.1 (1.0)

0.008

0.01

Serum biochemical markers, mean (se)

α2-macroglobulin (g/L)

1.70 (0.05)

1.70 (0.10)

0.74

1.72 (0.06)

1.76 (0.08)

0.47

0.50

ALT (IU)

72 (3)

63 (5)

0.10

79 (5)

84 (10)

0.69

0.35

AST (IU)

50 (3)

44 (3)

0.10

45 (3)

52 (5)

0.05

0.006

Apolipoprotein A1(g/L)

1.47 (0.02)

1.45 (0.06)

0.98

1.59 (0.07)

1.53 (0.04)

0.80

0.06

GGT (IU/L)

111 (12)

108 (15)

0.83

132 (12)

158 (19)

0.16

0.04

Haptoglobin (g/L)

1.09 (0.04)

1.18 (0.11)

0.41

1.12 (0.10)

1.02 (0.05)

0.70

0.39

Total bilirubin (μmol/L)

11.4 (0.5)

22.1 (9.5)

0.35

12.6 (0.6)

13.6 (1.0)

0.89

0.02

Glucose (mmol/L)

6.1 (0.2)

5.3 (0.2)

0.08

6.1 (0.2)

5.8 (0.3)

0.008

0.46

Cholesterol (mmol/L)

5.5 (0.1)

5.5 (0.2)

0.87

5.4 (0.1)

5.5 (0.1)

0.57

0.84

Triglycerides (mmol/L)

2.0 (0.1)

1.6 (0.1)

0.31

1.4 (0.1)

1.3 (0.1)

0.03

0.04

FibroTest (0.00–1.00)

0.30 (0.02)

0.35 (0.05)

0.59

0.29 (0.02)

0.33 (0.02)

0.21

0.99

SteatoTest (0.00–1.00)

0.70 (0.01)

0.56 (0.05)

0.007

0.61 (0.03)

0.60 (0.03)

0.54

0.02


NA=Not applicable as patients excluded have other associated diseases

* = among the 24 patients excluded 20 had no steatosis and 4 had steatosis < 5%

Poynard et al. BMC Gastroenterology 2006 6:34   doi:10.1186/1471-230X-6-34

Open Data